Patients with chronic hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


Patients with chronic hepatitis C could be treated with Sofosbuvir/Velpatasvir for 12 weeks by non-specialists: 2nd interim analysis of prospective study Helios-3

	AASLD Nov 4-8 2022